Newsletter – July 2026
July 1, 2026
- Newsletter
The July 2026 newsletter celebrates scientific achievements and the people, partnerships and resources supporting innovation at Fitzsimons Innovation Community. President and CEO Kelly Brough reflects on Colorado’s growing competitiveness in the life sciences industry and the collaborative environment that helps companies advance from discovery to commercialization. The Innovation Spotlight recognizes HepQuant for receiving FDA approval for its SHUNT® Liver Diagnostic Test, an important advancement in assessing complications associated with liver disease.
The newsletter also examines the expanding role of artificial intelligence in drug discovery, including evolving FDA and European Medicines Agency guidance, regulatory expectations and the importance of scientific validation. Additional coverage welcomes Antoinette Gawin, President and CEO of Terumo Blood and Cell Technologies, to the Fitzsimons Board of Directors and highlights Chief Operating Officer Kenneth Ho’s participation in a regional discussion about biotechnology, quantum technology and economic development. Readers will also find information about the Summer BBQ and E-Recycling Event, along with upcoming opportunities involving biotechnology investment, workforce development and entrepreneurship.
